NASDAQ:TXMD

TherapeuticsMD Q3 2025 Earnings Results & Report

TherapeuticsMD logo
$1.71 -0.10 (-5.52%)
As of 11/20/2026 04:00 PM Eastern

TherapeuticsMD reported Q3 2025 earnings on November 12, 2025. The company reported EPS of $0.0131, while revenue was $784 thousand.

Earnings Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Conference Call
6:00 AM ET

TherapeuticsMD EPS Results

Actual EPS
$0.0131
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

TherapeuticsMD Revenue Results

Actual Revenue
$784 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TherapeuticsMD Q3 2025 Earnings FAQ

TherapeuticsMD (NASDAQ:TXMD) reported earnings of $0.0131 per share for Q3 2025. The report was announced on Wednesday, November 12, 2025.

TherapeuticsMD reported revenue of $784 thousand for Q3 2025.

TherapeuticsMD Earnings Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) was a U.S. women’s health pharmaceutical company that developed and commercialized prescription products addressing contraception and symptoms associated with menopause. Its business was primarily focused on the U.S. market.

The company’s products included ANNOVERA, a reusable contraceptive vaginal system; IMVEXXY, estradiol vaginal inserts prescribed for certain menopausal symptoms; and BIJUVA, an oral estradiol and progesterone treatment for moderate-to-severe vasomotor symptoms associated with menopause in eligible women.

In 2023, TherapeuticsMD sold substantially all of its assets, including rights to these products, to Mayne Pharma. The products and commercial activities described here reflect TherapeuticsMD’s historical business.

View TherapeuticsMD Profile